Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
Volume 0.10M
Average 2.07M
GUTS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Fractyl Health, Inc. Common StockNASDAQ: GUTS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $9.5M, compared with -$23.45M a year earlier. Trailing-twelve-month EBITDA was -$106.88M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$51.57M (+63.1%) for the fiscal year ending Dec 2026, a step up from the -105.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $9.5M+121.9% QoQ
- Last fiscal yearDec 2025
- -$139.83M-105.6% YoY
- LTMMar 2026
- -$106.88M-21.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +140.5% | — | — |
| 1 year | -105.6% | +63.1% | +168.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (139.83M) USD
- Year-over-year change
- -105.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (139.83M) | -105.6% |
| FY2024 | 2024-12-31 | (68.02M) | +11.4% |
| FY2023 | 2023-12-31 | (76.81M) | -67.0% |
| FY2022 | 2022-12-31 | (46M) | -25.6% |
| FY2021 | 2021-12-31 | (36.62M) | — |
EBITDA vs competitors
How GUTS compares with its peers on the latest reported figures
- GUTS's LTM Mar 2026 EBITDA of -$106.88M is the lowest of the 7 companies compared; the peer median is -$76.56M.
- Its year-over-year change of -21.2% is the 5th highest of 7, against a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$40.42M | -143.9% | — | 89.7% | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$68.69M | -10.6% | — | 36154.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M | -35.4% | — | — |
| LTM Mar 2026 | -$86.7M | +32.0% | — | — | |
| LTM Mar 2026 | -$106.12M | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$106.88M | -21.2% | — | — | |
| Peer median (excluding GUTS) | -$76.56M | +10.7% | — | 106.5% | |
Competitors are the stored peer set for GUTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 120K | 93K | 0 |
| Cost of Revenue | 0 | 452K | 77K | 50K | 0 |
| Gross Profit | 0 | (452K) | 43K | 43K | 0 |
| Gross Margin | — | — | 35.8% | 46.2% | — |
| Research & Development | 26.44M | 34.35M | 38.04M | 70.47M | 74.54M |
| Selling, General & Admin | 10.49M | 14.58M | 0 | 0 | 22.28M |
| Operating Expenses | 36.93M | 48.93M | 50.88M | 93.57M | 96.82M |
| Depreciation & Amortization | 676K | 452K | 286K | 677K | 1.13M |
| EBITDA | (36.62M) | (46M) | (76.81M) | (68.02M) | (139.83M) |
| EBITDA Margin | — | — | -64004.2% | -73136.6% | — |
| Operating Income | (36.93M) | (49.39M) | (50.84M) | (93.53M) | (96.82M) |
| Operating Margin | — | — | -42363.3% | -100571.0% | — |
| Interest Income | 0 | 797K | 1.26M | 4.15M | 1.54M |
| Interest Expense | 1.44M | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.81M) | 2.93M | (26.26M) | 24.84M | (44.14M) |
| Income Before Tax | (38.74M) | (46.45M) | (77.09M) | (68.69M) | (140.95M) |
| Pre-Tax Margin | — | — | -64242.5% | -73864.5% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (38.74M) | (46.45M) | (77.09M) | (68.69M) | (140.95M) |
| Net Margin | — | — | -64242.5% | -73864.5% | — |
| EPS (Basic) | (1.12) | (1.34) | (1.98) | (1.62) | (1.86) |
| EPS (Diluted) | (1.12) | (1.34) | (1.98) | (1.62) | (1.86) |
| Weighted Avg Shares | 47.61M | 47.61M | 47.61M | 43.54M | 75.82M |
| Weighted Avg Shares (Diluted) | 47.61M | 47.61M | 47.61M | 43.54M | 75.82M |
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
Intrinsic Alpha fair value
Locked
Current Price
$4.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.